Skip to main content
World Today News
  • Home
  • News
  • World
  • Sport
  • Entertainment
  • Business
  • Health
  • Technology
Menu
  • Home
  • News
  • World
  • Sport
  • Entertainment
  • Business
  • Health
  • Technology

Experimental Compound TOFA Raises Energy Expenditure 18% in Obese Mice, UC Berkeley Study Finds

November 20, 2026 Health Desk Health

TOFA, an experimental compound from UC Berkeley, raised the energy expenditure of obese mice by up to 18% while the animals lost fat and kept their lean muscle mass.

That figure, reported in Science Advances and covered by ScienceDaily, arrives as existing GLP-1 weight-loss drugs — Ozempic, Wegovy, Mounjaro, Zepbound — deliver large appetite-driven weight loss but can strip away muscle along the way.

Key Clinical Takeaways:

  • The compound TOFA increased energy expenditure in obese mice by up to 18%, without more exercise or higher body temperature.
  • Mice lost weight mainly as fat, with insulin sensitivity, triglycerides, and fatty liver markers all improving.
  • Combined with semaglutide or tirzepatide, TOFA produced better metabolic results than either drug alone, in mouse studies.
  • No human data exist yet; the Berkeley team has formed a biotech company, ReRx Therapeutics, to push the work forward.

The research matters because of what it attacks on the other side of the energy balance. GLP-1 drugs such as semaglutide, the active ingredient in Ozempic and Wegovy, and tirzepatide, sold as Mounjaro and Zepbound, work almost entirely by cutting appetite and food intake.

That mechanism transformed obesity and diabetes care over the past five years, but it carries drawbacks ScienceDaily detailed in its report: nausea and other digestive problems, a risk of inadequate nutrition, and loss of lean muscle that over time can contribute to weakness and frailty.

“Body weight responds to two levers: taking in fewer calories, or spending more energy,” said Anders Näär, a professor of metabolic biology and nutrition at UC Berkeley and senior author of the study. “GLP-1s work almost entirely on the first, so we went after the second.”

Experimental compound burns fat without sacrificing muscle
Photo: ncijnetwork.com

What TOFA does to fat metabolism

The molecule, 5-tetradecyloxy-2-furoic acid, was first discovered in the 1970s. The Berkeley team’s new work, published in Science Advances, uncovered a dual action that distinguishes it from related compounds. TOFA belongs to a class called ACC inhibitors, which block enzymes the body uses to manufacture fatty acids.

Other ACC inhibitors have reached mid-stage clinical trials, but none has been approved for metabolic disease, largely because many of them raise blood triglycerides — a change that could raise heart risk.

TOFA does something the others in its class do not. Beyond blocking lipid synthesis, it activates two cellular receptors, PPARα and PPARδ, which the study describes as molecular switches governing fat uptake and burning. The compound simultaneously slows fat production and speeds fat consumption.

“TOFA appears to engage a coordinated metabolic response,” said study first author Justin Y. Lee, a postdoctoral student at UCSF who conducted the research as a Ph.D. student at Berkeley. “It is not simply blocking lipid synthesis. It is also activating energy expenditure pathways that may help the body handle excess lipid and glucose more effectively.”

Energy expenditure rose 18% without movement

In obese mice, treatment improved insulin sensitivity, lowered triglycerides, and improved characteristics of fatty liver disease, according to the study. Weight loss came primarily from body fat, without a large drop in lean muscle mass. Energy expenditure rose by as much as 18% even though the mice did not move more and their body temperature did not climb — two routes by which such an increase might otherwise be explained.

The triglyceride result stands out against the class’s history. Unlike other ACC inhibitors, TOFA did not push triglycerides higher, possibly because of its additional effects on fat metabolism, the researchers report.

Why one molecule beat two

To test whether TOFA’s two effects could be reproduced separately, the scientists gave mice a combination of two compounds — one blocking lipid production, the other stimulating energy expenditure. The pairing worked worse than TOFA alone at improving overall metabolic health. The single molecule’s ability to hit several metabolic processes at once appears central to its effect, per the study.

Adding TOFA to Ozempic and Wegovy

The combination experiments extended to the blockbuster GLP-1 drugs themselves. When the researchers gave TOFA alongside semaglutide or tirzepatide in mice, the pairings produced greater improvements in body weight, blood glucose regulation, insulin levels, and triglycerides than either treatment alone, ScienceDaily reported.

“In our combination experiments, TOFA worked additively or synergistically with the GLP-1 appetite-suppressing drugs, so we view it as complementary rather than as a replacement,” Näär said.

The framing matters for clinicians and patients watching the obesity-treatment market. The researchers do not position TOFA as a successor to Ozempic or Wegovy; they describe a second mechanism that could eventually sit alongside appetite suppression — one targeting energy expenditure rather than intake.

From Berkeley lab to biotech

The Berkeley scientists have established a biotechnology company, ReRx Therapeutics, to move the research toward clinical application, with support from the university’s life sciences entrepreneurship network, including Nucleate and Berkeley SkyDeck.

Funding for the research was provided by discretionary resources from UC Berkeley, alongside assistance from the UCSF Liver Center and the University of Michigan Animal Phenotyping Core. Additional authors include researchers from Berkeley, Massachusetts General Hospital, UC San Diego, and the Helmholtz Center Munich, with Prabha Ibrahim of ReRx Therapeutics also listed.

Every result so far comes from animal studies. The study does not establish whether TOFA is safe or effective in humans, and further research is needed to determine whether the same metabolic improvements can be achieved in people and whether the compound would offer meaningful advantages over existing medications — limits the researchers themselves state.

For patients weighing GLP-1 therapy now, the practical questions — dosing, muscle preservation strategies, nutrition monitoring during rapid weight loss — remain the province of treating clinicians. An endocrinologist or obesity-medicine physician can assess whether a current GLP-1 regimen is producing excessive muscle loss, and a registered dietitian can help protect lean mass while intake drops. Patients with persistent fatty liver findings may need evaluation by a hepatologist.

If TOFA’s mouse results survive the translation to humans, the compound would add a second lever to a pharmacopoeia that has so far pulled only one. The next milestone sits with TOFA and the human trials that have yet to be scheduled — the step on which an 18% finding in mice will either hold or dissolve.

The work comes out of a university with deep roots in American science. UC Berkeley, founded in 1868 and named after the philosopher George Berkeley, is the founding campus of the University of California system and the state’s first land-grant university.

It opened in 1869 with ten faculty members and forty male students, and today enrolls more than 45,000 students across fifteen schools, including the College of Chemistry and the College of Engineering. Lawrence Berkeley National Laboratory was originally founded as part of the university, and campus research and development drew more than $1 billion in federal funding in 2021. Berkeley’s researchers count 65 Nobel laureates among their alumni, faculty, and affiliates.

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Worth a look

  • The Institute Framed the Case as Exposing Two Problems at Once
  • Three Couples Deliver IVF Babies at Gandhi Hospital After Failed Private Cycles

Related

Search:

World Today News

World Today News is your trusted source for global journalism — breaking headlines, in-depth analysis, and reporting from around the world.

Quick Links

  • Privacy Policy
  • About Us
  • Accessibility statement
  • California Privacy Notice (CCPA/CPRA)
  • Contact
  • Cookie Policy
  • Disclaimer
  • DMCA Policy
  • Do not sell my info
  • EDITORIAL TEAM
  • Terms & Conditions

Browse by Location

  • GB
  • NZ
  • US

Connect With Us

© 2026 World Today News. All rights reserved. Your trusted global news source directory.
For contact, advertising, copyright, issues email: [email protected]

Privacy Policy Terms of Service